Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Educational Efforts Are First Front Of Marketing Battle For PCSK9s

Executive Summary

With reams of PCSK9 data showing robust lowering of LDL – a trusted surrogate – under their belt, sponsors aim to win over prescribers, payers and patients ahead of outcomes trial releases.

You may also be interested in...



Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher

Alirocumab was associated with lower rate of major cardiovascular events compared to placebo in post-hoc, interim Phase III analysis – boosting chances for FDA approval in 2015. The firm is taking no chances on review period, purchasing a priority review voucher from BioMarin.

Preparing For Battle: PCSK9 Sponsors Stake Their Ground

The strong efficacy and sound safety data coming out of the Phase III programs presented at ACC have all eyes on the commercial opportunity for the PCSK9 inhibitor class. Ongoing outcomes trials and market impact of new cholesterol guidelines sparked discussion, and leading sponsors Amgen and Sanofi/Regeneron talked about the potential populations and differences in the devices and dosing of evolocumab and alirocumab.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS056518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel